Do analysts rate BFRG or ISPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BFRG or ISPC more profitable?

Bullfrog AI has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. Bullfrog AI's return on equity of -150.36% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets Bullfrog AI N/A -150.36% -127.98% iSpecimen -2,445.40% -524.39% -140.42%

Does the media favor BFRG or ISPC?

In the previous week, Bullfrog AI had 4 more articles in the media than iSpecimen. MarketBeat recorded 7 mentions for Bullfrog AI and 3 mentions for iSpecimen. Bullfrog AI's average media sentiment score of 0.83 beat iSpecimen's score of 0.26 indicating that Bullfrog AI is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bullfrog AI 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iSpecimen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ISPC or VIVS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, ISPC or VIVS?

iSpecimen has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iSpecimen $1.93M 1.65 -$10.49M -$56.44 N/A VivoSim Labs $112K 33.17 -$13.84M -$4.47 N/A

Is ISPC or VIVS more profitable?

iSpecimen has a net margin of -2,445.40% compared to VivoSim Labs' net margin of -11,016.07%. iSpecimen's return on equity of -524.39% beat VivoSim Labs' return on equity. Company Net Margins Return on Equity Return on Assets iSpecimen -2,445.40% -524.39% -140.42% VivoSim Labs -11,016.07% -612.23% -177.02%

Does the media prefer ISPC or VIVS?

In the previous week, VivoSim Labs had 1 more articles in the media than iSpecimen. MarketBeat recorded 4 mentions for VivoSim Labs and 3 mentions for iSpecimen. VivoSim Labs' average media sentiment score of 0.36 beat iSpecimen's score of 0.26 indicating that VivoSim Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iSpecimen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VivoSim Labs 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ISPC or TBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Telesis Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ISPC or TBIO more profitable?

Telesis Bio has a net margin of -336.59% compared to iSpecimen's net margin of -2,445.40%. Telesis Bio's return on equity of 0.00% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets iSpecimen -2,445.40% -524.39% -140.42% Telesis Bio -336.59% N/A -61.89%

Do analysts prefer BFRGW or ISPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, BFRGW or ISPC?

Bullfrog AI has higher earnings, but lower revenue than iSpecimen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bullfrog AI $298.80K N/A N/A N/A N/A iSpecimen $1.93M 1.65 -$10.49M -$56.44 N/A

Is BFRGW or ISPC more profitable?

Bullfrog AI has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. Bullfrog AI's return on equity of 0.00% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets Bullfrog AI N/A N/A N/A iSpecimen -2,445.40% -524.39% -140.42%

Does the media refer more to BFRGW or ISPC?

In the previous week, iSpecimen had 1 more articles in the media than Bullfrog AI. MarketBeat recorded 3 mentions for iSpecimen and 2 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 0.61 beat iSpecimen's score of 0.26 indicating that Bullfrog AI is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bullfrog AI 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iSpecimen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ISPC or OABIW?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 OmniAb 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, ISPC or OABIW?

OmniAb has higher revenue and earnings than iSpecimen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iSpecimen $1.93M 1.65 -$10.49M -$56.44 N/A OmniAb $38.46M N/A N/A N/A N/A

Is ISPC or OABIW more profitable?

OmniAb has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. OmniAb's return on equity of 0.00% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets iSpecimen -2,445.40% -524.39% -140.42% OmniAb N/A N/A N/A

iSpecimen (ISPC) Competitors

$1.26 +0.01 (+0.80%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$1.22 -0.04 (-3.10%)

As of 09/25/2026 07:59 PM Eastern

Compare

ISPC vs. BFRG, VIVS, TBIO, BFRGW, and OABIW

Should you buy iSpecimen stock or one of its competitors? iSpecimen's main competitors and comparable companies include Bullfrog AI (BFRG), VivoSim Labs (VIVS), Telesis Bio (TBIO), Bullfrog AI (BFRGW), and OmniAb (OABIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does iSpecimen compare to Bullfrog AI?

Bullfrog AI (NASDAQ:BFRG) and iSpecimen (NASDAQ:ISPC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

In the previous week, Bullfrog AI had 4 more articles in the media than iSpecimen. MarketBeat recorded 7 mentions for Bullfrog AI and 3 mentions for iSpecimen. Bullfrog AI's average media sentiment score of 0.83 beat iSpecimen's score of 0.26 indicating that Bullfrog AI is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bullfrog AI	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iSpecimen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bullfrog AI has a beta of -2.71, indicating that its share price is 371% less volatile than the broader market. Comparatively, iSpecimen has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bullfrog AI has higher earnings, but lower revenue than iSpecimen. Bullfrog AI is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$298.80K	41.30	-$6.50M	-$0.46	N/A
iSpecimen	$1.93M	1.65	-$10.49M	-$56.44	N/A

1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 13.6% of iSpecimen shares are held by institutional investors. 14.7% of Bullfrog AI shares are held by insiders. Comparatively, 12.2% of iSpecimen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Bullfrog AI has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. Bullfrog AI's return on equity of -150.36% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-150.36%	-127.98%
iSpecimen	-2,445.40%	-524.39%	-140.42%

Summary

Bullfrog AI beats iSpecimen on 10 of the 14 factors compared between the two stocks.

How does iSpecimen compare to VivoSim Labs?

iSpecimen (NASDAQ:ISPC) and VivoSim Labs (NASDAQ:VIVS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

iSpecimen has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$1.93M	1.65	-$10.49M	-$56.44	N/A
VivoSim Labs	$112K	33.17	-$13.84M	-$4.47	N/A

13.6% of iSpecimen shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 12.2% of iSpecimen shares are owned by insiders. Comparatively, 1.0% of VivoSim Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

iSpecimen has a net margin of -2,445.40% compared to VivoSim Labs' net margin of -11,016.07%. iSpecimen's return on equity of -524.39% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iSpecimen	-2,445.40%	-524.39%	-140.42%
VivoSim Labs	-11,016.07%	-612.23%	-177.02%

In the previous week, VivoSim Labs had 1 more articles in the media than iSpecimen. MarketBeat recorded 4 mentions for VivoSim Labs and 3 mentions for iSpecimen. VivoSim Labs' average media sentiment score of 0.36 beat iSpecimen's score of 0.26 indicating that VivoSim Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iSpecimen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VivoSim Labs	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

iSpecimen has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

iSpecimen beats VivoSim Labs on 9 of the 13 factors compared between the two stocks.

How does iSpecimen compare to Telesis Bio?

iSpecimen (NASDAQ:ISPC) and Telesis Bio (NASDAQ:TBIO) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

13.6% of iSpecimen shares are owned by institutional investors. Comparatively, 37.6% of Telesis Bio shares are owned by institutional investors. 12.2% of iSpecimen shares are owned by insiders. Comparatively, 24.5% of Telesis Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Telesis Bio has a net margin of -336.59% compared to iSpecimen's net margin of -2,445.40%. Telesis Bio's return on equity of 0.00% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iSpecimen	-2,445.40%	-524.39%	-140.42%
Telesis Bio	-336.59%	N/A	-61.89%

iSpecimen has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market. Comparatively, Telesis Bio has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market.

In the previous week, iSpecimen had 3 more articles in the media than Telesis Bio. MarketBeat recorded 3 mentions for iSpecimen and 0 mentions for Telesis Bio. iSpecimen's average media sentiment score of 0.26 beat Telesis Bio's score of 0.00 indicating that iSpecimen is being referred to more favorably in the media.

Company	Overall Sentiment
iSpecimen	Neutral
Telesis Bio	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Telesis Bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

iSpecimen has higher earnings, but lower revenue than Telesis Bio. iSpecimen is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$1.93M	1.65	-$10.49M	-$56.44	N/A
Telesis Bio	$225.09M	0.00	-$47.72M	-$20.52	N/A

Summary

Telesis Bio beats iSpecimen on 9 of the 14 factors compared between the two stocks.

How does iSpecimen compare to Bullfrog AI?

Bullfrog AI (NASDAQ:BFRGW) and iSpecimen (NASDAQ:ISPC) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, iSpecimen had 1 more articles in the media than Bullfrog AI. MarketBeat recorded 3 mentions for iSpecimen and 2 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 0.61 beat iSpecimen's score of 0.26 indicating that Bullfrog AI is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bullfrog AI	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iSpecimen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bullfrog AI has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. Bullfrog AI's return on equity of 0.00% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	N/A	N/A
iSpecimen	-2,445.40%	-524.39%	-140.42%

13.6% of iSpecimen shares are held by institutional investors. 12.2% of iSpecimen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bullfrog AI has higher earnings, but lower revenue than iSpecimen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$298.80K	N/A	N/A	N/A	N/A
iSpecimen	$1.93M	1.65	-$10.49M	-$56.44	N/A

Summary

iSpecimen beats Bullfrog AI on 5 of the 9 factors compared between the two stocks.

How does iSpecimen compare to OmniAb?

iSpecimen (NASDAQ:ISPC) and OmniAb (NASDAQ:OABIW) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

In the previous week, iSpecimen had 2 more articles in the media than OmniAb. MarketBeat recorded 3 mentions for iSpecimen and 1 mentions for OmniAb. OmniAb's average media sentiment score of 1.82 beat iSpecimen's score of 0.26 indicating that OmniAb is being referred to more favorably in the news media.

Company	Overall Sentiment
iSpecimen	Neutral
OmniAb	Very Positive

OmniAb has a net margin of 0.00% compared to iSpecimen's net margin of -2,445.40%. OmniAb's return on equity of 0.00% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iSpecimen	-2,445.40%	-524.39%	-140.42%
OmniAb	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
OmniAb	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

OmniAb has higher revenue and earnings than iSpecimen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$1.93M	1.65	-$10.49M	-$56.44	N/A
OmniAb	$38.46M	N/A	N/A	N/A	N/A

Summary

OmniAb beats iSpecimen on 5 of the 9 factors compared between the two stocks.

Get iSpecimen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ISPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ISPC vs. The Competition

Export

Metric	iSpecimen	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.15M	$10.94B	$7.29B	$13.12B
Dividend Yield	N/A	1.45%	2.52%	13.50%
P/E Ratio	-0.02	73.84	275.84	25.78
Price / Sales	1.65	107.19	618.88	84.19
Price / Cash	N/A	27.70	79.23	52.93
Price / Book	0.09	6.07	10.44	6.30
Net Income	-$10.49M	$56.67B	$3.51B	$360.35M
7 Day Performance	-5.26%	2.34%	-1.31%	-0.23%
1 Month Performance	-23.17%	2.53%	-4.72%	-3.87%
1 Year Performance	-97.31%	41.07%	14.97%	5.38%

iSpecimen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ISPC iSpecimen	0.4288 of 5 stars	$1.26 +0.8%	N/A	-97.6%	$3.15M	$1.93M	N/A	7	News Coverage Short Interest Increase Gap Up
BFRG Bullfrog AI	1.8731 of 5 stars	$0.45 -4.9%	N/A	-53.5%	$8.74M	$120K	N/A	4	News Coverage
VIVS VivoSim Labs	0.6863 of 5 stars	$0.27 -3.1%	N/A	-93.5%	$4.66M	$130K	N/A	20	Positive News
TBIO Telesis Bio	N/A	$0.00 flat	N/A	-99.2%	$2K	$225.09M	N/A	200
BFRGW Bullfrog AI	N/A	$0.08 -0.4%	N/A	-66.5%	$0.00	$298.80K	N/A	2	News Coverage Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ISPC) was last updated on 9/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iSpecimen (ISPC) Competitors

ISPC vs. BFRG, VIVS, TBIO, BFRGW, and OABIW

How does iSpecimen compare to Bullfrog AI?

Summary

How does iSpecimen compare to VivoSim Labs?

Summary

How does iSpecimen compare to Telesis Bio?

Summary

How does iSpecimen compare to Bullfrog AI?

Summary

How does iSpecimen compare to OmniAb?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ISPC vs. The Competition

iSpecimen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iSpecimen (ISPC) Competitors

ISPC vs. BFRG, VIVS, TBIO, BFRGW, and OABIW

How does iSpecimen compare to Bullfrog AI?

Does the media favor BFRG or ISPC?

Which has more volatility & risk, BFRG or ISPC?

Do analysts rate BFRG or ISPC?

Which has higher earnings and valuation, BFRG or ISPC?

Do insiders & institutionals believe in BFRG or ISPC?

Is BFRG or ISPC more profitable?

Summary

How does iSpecimen compare to VivoSim Labs?

Which has stronger valuation & earnings, ISPC or VIVS?

Do insiders and institutionals have more ownership in ISPC or VIVS?

Is ISPC or VIVS more profitable?

Does the media prefer ISPC or VIVS?

Which has more risk & volatility, ISPC or VIVS?

Do analysts prefer ISPC or VIVS?

Summary

How does iSpecimen compare to Telesis Bio?

Do insiders and institutionals hold more shares of ISPC or TBIO?

Is ISPC or TBIO more profitable?

Which has more volatility and risk, ISPC or TBIO?

Does the media refer more to ISPC or TBIO?

Do analysts rate ISPC or TBIO?

Which has preferable earnings & valuation, ISPC or TBIO?

Summary

How does iSpecimen compare to Bullfrog AI?

Do analysts prefer BFRGW or ISPC?

Does the media refer more to BFRGW or ISPC?

Is BFRGW or ISPC more profitable?

Do insiders & institutionals hold more shares of BFRGW or ISPC?

Which has stronger valuation and earnings, BFRGW or ISPC?

Summary

How does iSpecimen compare to OmniAb?

Does the media prefer ISPC or OABIW?

Is ISPC or OABIW more profitable?

Do analysts recommend ISPC or OABIW?

Which has stronger earnings and valuation, ISPC or OABIW?

Do insiders & institutionals have more ownership in ISPC or OABIW?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ISPC vs. The Competition

iSpecimen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools